An investigator-sponsored Phase 3b Open-label Study of Anti-FGF23 Antibody Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH) in GERmany - BurGER
Latest Information Update: 24 Jul 2023
At a glance
- Drugs Burosumab (Primary)
- Indications X-linked dominant hypophosphataemic rickets
- Focus Therapeutic Use
- Acronyms BurGER
- 15 Jan 2023 Status changed from active, no longer recruiting to completed.
- 26 Apr 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Nov 2022.
- 26 Apr 2022 Status changed from recruiting to active, no longer recruiting.